TY - JOUR
T1 - Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer
AU - Harris, Lyndsay N.
AU - You, Fanglei
AU - Schnitt, Stuart J.
AU - Witkiewicz, Agnes
AU - Lu, Xin
AU - Sgroi, Dennis
AU - Ryan, Paula D.
AU - Come, Steven E.
AU - Burstein, Harold J.
AU - Lesnikoski, Beth Ann
AU - Kamma, Madhavi
AU - Friedman, Paula N.
AU - Gelman, Rebecca
AU - Iglehart, J. Dirk
AU - Winer, Eric P.
PY - 2007/2/15
Y1 - 2007/2/15
N2 - Purpose: To assess pathologic complete response (pCR), clinical response, feasibility, safety, and potential predictors of response to preoperative trastuzumab plus vinorelbine in patients with operable, human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Experimental Design: Forty-eight patients received preoperative trastuzumab and vinorelbine weekly for 12 weeks. Single and multigene biomarker studies were done in an attempt to identify predictors of response. Results: Eight of 40 (20%) patients achieved pCR (95% confidence interval, 9-36%). Of 9 additional patients recruited for protocol-defined toxicity analysis, 8 were evaluable; 42 of 48 (88%) patients had clinical response (16 patients, clinical complete response; 26 patients, clinical partial response). T1 tumors more frequently exhibited clinical complete response (P = 0.05) and showed a trend to exhibit pCR (P = 0.07). Five (13%) patients experienced grade 1 cardiac dysfunction during preoperative treatment. Neither HER2 nor estrogen receptor status changed significantly after exposure to trastuzumab and vinorelbine. RNA profiling identified three top-level clusters by unsupervised analysis. Tumors with extremes of response [pCR (n = 3) versus nonresponse (n = 3)] fell into separate groups by hierarchical clustering. No predictive genes were identified in pCR tumors. Nonresponding tumors were more likely to be T4 stage (P = 0.02) and express basal markers (P < 0.00001), growth factors, and growth factor receptors. Insulin-like growth factor-1 receptor membrane expression was associated with a lower response rate (50% versus 97%; P = 0.001). Conclusions: Preoperative trastuzumab plus vinorelbine is active and well tolerated in patients with HER2-positive, operable, stage II/III breast cancer. HER2-overexpressing tumors with a basal-like phenotype, or with expression of insulin-like growth factor-1 receptor and other proteins involved in growth factor pathways, are more likely to be resistant to this regimen.
AB - Purpose: To assess pathologic complete response (pCR), clinical response, feasibility, safety, and potential predictors of response to preoperative trastuzumab plus vinorelbine in patients with operable, human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Experimental Design: Forty-eight patients received preoperative trastuzumab and vinorelbine weekly for 12 weeks. Single and multigene biomarker studies were done in an attempt to identify predictors of response. Results: Eight of 40 (20%) patients achieved pCR (95% confidence interval, 9-36%). Of 9 additional patients recruited for protocol-defined toxicity analysis, 8 were evaluable; 42 of 48 (88%) patients had clinical response (16 patients, clinical complete response; 26 patients, clinical partial response). T1 tumors more frequently exhibited clinical complete response (P = 0.05) and showed a trend to exhibit pCR (P = 0.07). Five (13%) patients experienced grade 1 cardiac dysfunction during preoperative treatment. Neither HER2 nor estrogen receptor status changed significantly after exposure to trastuzumab and vinorelbine. RNA profiling identified three top-level clusters by unsupervised analysis. Tumors with extremes of response [pCR (n = 3) versus nonresponse (n = 3)] fell into separate groups by hierarchical clustering. No predictive genes were identified in pCR tumors. Nonresponding tumors were more likely to be T4 stage (P = 0.02) and express basal markers (P < 0.00001), growth factors, and growth factor receptors. Insulin-like growth factor-1 receptor membrane expression was associated with a lower response rate (50% versus 97%; P = 0.001). Conclusions: Preoperative trastuzumab plus vinorelbine is active and well tolerated in patients with HER2-positive, operable, stage II/III breast cancer. HER2-overexpressing tumors with a basal-like phenotype, or with expression of insulin-like growth factor-1 receptor and other proteins involved in growth factor pathways, are more likely to be resistant to this regimen.
UR - http://www.scopus.com/inward/record.url?scp=33947246109&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33947246109&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-06-1304
DO - 10.1158/1078-0432.CCR-06-1304
M3 - Article
C2 - 17317830
AN - SCOPUS:33947246109
SN - 1078-0432
VL - 13
SP - 1198
EP - 1207
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 4
ER -